|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A significant difference in PD-L1 expression between squamous-cell carcinoma and adenocarcinoma was observed with odds ratio for adenocarcinoma 1.8.
|
31383957 |
2020 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PD-L1 expression was more frequent in medullary and typical adenocarcinoma than in mucinous adenocarcinoma based on combined positive scores.
|
31152546 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PD-L1 mRNA expression was also significantly correlated with HIF1A, VEGFA, GLUT1, and CAIX expression in adenocarcinoma.
|
30797490 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed in our series of 129 colorectal adenocarcinomas that PD-L1 expression occurred primarily in tumor-associated-immune cells and most prominently at the tumor-stroma-interface of the invasive front.
|
30166615 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Eligible patients were aged 20-79 years, had biliary tract adenocarcinoma (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer), Eastern Cooperative Oncology Group performance status 0 or 1, adequate hepatic, renal, and haematological function, and tumour tissue samples for PD-L1 expression analysis.
|
31109808 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Validation cohorts including our biobank confirmed that the AXL expression significantly correlated with expression of genes encoding programmed death-ligand1 (PD-L1) and CXC chemokine receptor 6 (CXCR6) in lung adenocarcinoma, especially in epidermal growth factor receptor (EGFR) mutation-positive adenocarcinoma.
|
30744655 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Together with PD-L1 expression, EGFR mutation status is an important factor to predict the efficacy of PD-1/PD-L1 inhibitors in patients with pulmonary adenocarcinoma.
|
30900155 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results show that the two subtypes of adenocarcinoma of the AOV exhibit significant differences in tumoral PD-L1 expression and intratumoral CD8<sup>+</sup> T lymphocyte density, which might contribute to their distinct clinical features.
|
30604042 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PD-L1 expression in tumor cells was only seen in 3% (1/34) of ductal and 5% (2/42) of acinar adenocarcinomas (p = 1.0), while PD-L1 expression in tumor-infiltrating immune cells was seen in 29% (10/34) of ductal and 14% (6/42) of acinar adenocarcinomas (p = 0.16). dMMR, as defined by loss of one or more of the MMR proteins, was identified in 5% (4/73) of cases, including 1 ductal and 3 acinar adenocarcinomas.
|
31127651 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A predominant adenocarcinoma epithelial component in PPC might be associated with better survival outcomes and high PD-L1 expression might be frequent in PPC.
|
31570483 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (<i>p</i> = 0.0332) in adenocarcinoma (AC) only.
|
30769852 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among 188 patients with curatively resected NSCLC, 127 adenocarcinomas and 61 squamous cell carcinomas were stained for PD-L1 and vimentin expression.
|
31546725 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 80 tumor tissue samples and 30 paired histologically normal lung tissue samples from 30 patients with adenocarcinoma in situ (AIS) (n = 8), minimally invasive adenocarcinoma (MIA) (n = 8), and invasive adenocarcinoma (IAC) (n = 14) were subjected to multiregion whole exome sequencing and immunohistochemistry staining for CD8 and programmed death ligand 1 (PD-L1).
|
31446140 |
2019 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Females 63%; adenocarcinoma (AC)/squamous/others 69%/23%/8%; ECOG ≥ 2 10%; bone/brain/liver metastases 36%/18%/15%; PD-L1 (TPS) <1%/ ≥ 1%/ ≤ 49%/ ≥ 50%/NR: 3%/14%/68%/15%; baseline autoimmunity 10%, Charlson's Comorbidity Index Score (CCIS) ≥ 2 39%, treatment line: 1st/2nd/ ≥ 3rd 39%/30%/31%.
|
31081424 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Following immunohistochemical analysis of PD-L1 in surgically resected pN0M0 NSCLC (n = 125, including 88 invasive adenocarcinomas and 37 squamous cell carcinomas), the correlation of PD-L1-positive CAFs with clinicopathological features was investigated.
|
31546072 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The immune microenvironment, including PD-L1 expression, and its impact on prognosis showed clear differences in AD and SCC gene expression subtypes.
|
30854794 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<b>Methods:</b> Immunohistochemical expression of PD-L1 on tumour cells (TC) and tumour-infiltrating immune cells (TIC), and of PD-1 (programmed death receptor 1) on TIC was assessed using tissue microarrays with primary tumours and a subset of paired lymph node metastases from a consecutive, retrospective cohort of 174 patients with chemoradiotherapy-naïve EG adenocarcinoma.
|
30931254 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Programmed Death Ligand 1(PD-L1) testing is recommended for patients with Non-Small Cell Lung Cancer (NSCLC) at stage IIIB and IV, adenocarcinoma and squamous cell carcinoma.
|
30879776 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Objective response rate was 14.3% (95% CI, 6.7%-25.4%) among patients with ESCC (9 of 63), 5.2% (95% CI, 1.1%-14.4%) among patients with adenocarcinoma (3 of 58), 13.8% (95% CI, 6.1%-25.4%) among patients with PD-L1-positive tumors (8 of 58), and 6.3% (95% CI, 1.8%-15.5%) among patients with PD-L1-negative tumors (4 of 63).
|
30570649 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PD-L1 expression was adversely associated with epidermal growth factor receptor mutation status (P < .001) and was significantly associated with invasive adenocarcinomas rather than preinvasive lesions and minimally invasive adenocarcinomas (P < .001).
|
30514666 |
2019 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The value of the maximum standardized uptake value (SUV<sub>max</sub>) for [<sup>18</sup>F]FAMT was significantly correlated with PD-L1 (E1L3N) expression, Glut1, and the SUV<sub>max</sub> for [<sup>18</sup>F]FDG in patients with histological results of adenocarcinoma (AC) and advanced disease.
|
31792836 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A higher prevalence of PD-L1-positive cases was observed among esophageal specimens compared with gastric ones (p = 0.0003), in high-grade and adenocarcinoma samples in comparison with low-grade dysplasia (p < 0.0001), and in lesions with mismatch repair deficiency (p = 0.028).
|
31724072 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
|
31043417 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
PD-L1-positive tumors were frequent in acinar predominant adenocarcinoma and solid predominant adenocarcinoma than other adenocarcinoma subtypes.
|
30282880 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
PD-L1 Tumor Proportion Score was higher in squamous cell carcinomas (p = 0.004) and lower in adenocarcinomas (p = 0.003).
|
30401947 |
2019 |